This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia
Countries shortcomings in tackling antibiotic resistance spotlighted umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.
Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
News provided by
Share this article
Share this article
BANGALORE, India, April 26, 2021 /PRNewswire/ Bugworks Research, Inc ( Bugworks ), secures funding from the Defense Threat Reduction Agency (DTRA) to support development of its novel broad-spectrum antibiotic BWC0977, against the most critical bacterial biothreats.
DTRA will provide funding, through its Bacterial Rapid Acquisition Platform program, to support the nonclinical biodefense aspects of the development of BWC0977, including execution of in vivo efficacy studies to test BWC0977 against biothreat bacterial pathogens, beginning with
Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.